Skip to contentX
Xenon Pharmaceuticals Inc.
X
XENEXenon Pharmaceuticals Inc. Q1 2023 · 10-Q
Revenue—
Net Income-$41.73M-$41.73MN/M vs Q1 2022 EPS Diluted-$0.63-$0.63N/M vs Q1 2022 Operating Income-$49,051,000N/M Operating Cash Flow-$34,411,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
Free Cash Flowderived-$36,617,000N/M ended Mar 31, 2023 · filed May 9, 2023 · 39 d after period end